UGT1A1 and chronic myelogenous leukemia, BCR-ABL1 positive: A retrospective case-series including eight Japanese patients with CML receiving nilotinib found three UGT1A1 PMs (two *6 homozygotes, one *6/*28 compound heterozygote) experienced high-grade adverse events.